FSK adopted a poison pill to block Saba Capital. For KKR shareholders, the real risk is in the BDC's bond portfolio and borrowing spreads. Next catalyst: Saba's 13D filing.
FS KKR Capital Corp. (FSK) adopted a poison pill on March 24, blocking any person or group from acquiring 15% or more of its common stock without board approval. The move targets activist investor Saba Capital, which holds roughly a 5% position in the business development company. For shareholders of KKR & Co. Inc. (KKR), the story is not just a BDC governance fight. It exposes a credit portfolio risk that the equity market has not yet priced.
FSK's board approved a limited-duration shareholder rights plan. The trigger is set at 15% ownership. Saba has not crossed that threshold. The pill walls off Saba from building a controlling stake that could force a portfolio liquidation or a tender at net asset value. FSK trades at a discount to its NAV of roughly $23 per share. Saba's model profits by agitating for a tender at NAV, extracting the discount arbitrage at the expense of remaining shareholders.
KKR's exposure runs through two channels. The first is the equity stake, which is publicly visible. The second is the credit relationship: KKR provides financing and co-investment capital to FSK. If Saba were to win board seats and push for a sale or runoff of the BDC's portfolio, the bond holdings within that portfolio would be sold into potentially thin markets. A forced liquidation of below-investment-grade corporate debt clears at whatever the market will pay in a given week. That price is almost certainly lower than the adjusted book value FSK reports. For KKR's own credit funds that hold similar middle-market exposures, a visible forced liquidation price would become the worst-case comp.
FSK's net asset value per share stood at roughly $23 as of the last filing. The stock trades at a discount, which is why Saba sees an opportunity. Saba's model works by agitating for the BDC to tender shares at NAV, a premium to the market price. If successful, Saba extracts the discount arbitrage. The cost is borne by the remaining shareholders and, in the case of FSK, by KKR, which holds a significant equity stake.
KKR's exposure goes through two channels. The first is the equity stake, which is publicly visible. The second is the credit relationship: KKR provides financing and co-investment capital to FSK. If FSK's cost of capital rises because Saba's activism makes the BDC riskier to lenders, KKR's own financing costs for its credit platform could edge higher. No single number will show this in a quarterly filing. It would show first in the borrowing spreads that FSK pays on its unsecured notes. A widening spread is the canary; the equity price is the lag.
The poison pill filing triggered a standard sell-off in FSK shares, which dropped roughly 2% the day after the announcement. KKR shares were relatively flat. The market is pricing the FSK story as an idiosyncratic BDC fight, not a broader KKR credit event. That assessment may be correct as long as the fight stays rhetorical. It would break down if Saba pushed for a shareholder vote on portfolio liquidation, because liquidation timelines force price discovery in illiquid corporate bonds.
The next decision point is the Saba 13D filing, which is required within 10 days of the cross-ownership threshold. That filing will reveal whether Saba is already in discussions with other BDC shareholders or has built a larger position through total return swaps. If the filing shows a 10% or greater economic interest, the poison pill triggers a legal fight and the timeline for a proxy contest accelerates.
KKR carries an Alpha Score of 36/100, which the model labels Mixed. The Financials sector score is weighed down by the BDC exposure and by KKR's heavy allocation to illiquid private credit. The stock page at KKR stock page shows the score breakdown by factor. The model does not categorize this as a crisis, the Mixed label flags the portfolio as one where tail risk is underpriced. The FSK activism is the exact kind of second-order event that a low Alpha Score is meant to flag: an idiosyncratic position that can become a broader portfolio problem if the liquidity assumptions break.
A broader stock market analysis would place this in the context of rising BDC activism. Saba has targeted half a dozen closed-end funds and BDCs in the past year. The pattern is consistent. If FSK succeeds, it may slow Saba, it will not stop the cycle. Every BDC trading at a discount to NAV is now a potential target. KKR's core equity and credit books are not directly at risk, the mark-to-market on its FSK stake will be scrutinized at the next earnings call. The better trade is to watch the 13D filing date and the FSK borrowing spread rather than the equity price. A widening spread is the canary; the equity price is the lag.
The KKR shareholder who owns KKR for its private equity and credit returns should watch the FSK bond spread, not the FSK stock price. That spread is the cleanest signal of whether this activism is a distraction or a real portfolio event.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.